PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market
March 08 2021 - 11:32AM
InvestorsHub NewsWire
Sandusky, OH --
March 8, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today announced initiating the development of its new
nutraceutical, RELAX-RX, targeting the anxiety and depression
treatment market anticipated to reach a value
of $18 billion by
2025.
The company
recently announced plans to produce a variety of nutraceuticals for
additional applications beyond the current focus on care
for those
experiencing issues associated with Chronic Obstructive Pulmonary
Disorder (COPD).
Last year,
PAOG acquired
RespRx from Kali-Extracts, Inc. (OTC
Pink: KALY). RespRx is a cannabis treatment under development
for Chronic Obstructive Pulmonary Disorder (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS
PLANT."
PAOG plans to
develop and distribute its CBD nutraceuticals with Alkame Holdings,
Inc. (OTC
Pink: ALKM) as a copacker and North American Cannabis Holdings,
Inc. (OTC
Pink: USMJ) as a
distributor.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Oct 2023 to Oct 2024